In an attempt to develop gene therapy for thyroid carcinomas, the present studies were undertaken to evaluate in vitro and in vivo therapeutic efficacy and toxicity of herpes simplex virus thymidine kinase (HSV-tk) gene and ganciclovir (GCV) treatment, a widely used prodrug/suicide gene therapy, in human thyroid carcinoma cell lines, FRO and WRO cells, using a means of retrovirus-mediated gene transduction. In vitro experiments demonstrated dose-and time-dependent cell killing by transduction of the HSV-tk gene followed by GCV treatment. The IC 50 (the concentration required to elicit 50% growth inhibition) shifted from 250 to 0.5 mg/liter in FRO cells, and from 3,000 to 0.09 mg/liter in WRO cells with therapeutic indexes of 500 and 33,000, respectively. Treatment with 30 mg/liter GCV for 4 days led to complete cell death in HSV-tk tumor cells. Nontransduced cells mixed with transduced cells were also effectively killed by GCV (bystander effect). Low concentrations of GCV, which alone showed little cytotoxicity, enhanced radiation-induced cytotoxicity (radiosensitization). In vivo sc FRO-tk tumor models in nude mice also showed dose-and time-dependent tumor regression. The IC 50 was less than 2 mg/kg, and treatment with 100 mg/kg GCV for 2 weeks completely eradicated all tumors. The bystander effect and radiosensitization were also obtained in vivo. These results suggest that the HSV-tk/ GCV approach to human thyroid carcinoma cells appears to be very efficacious, with a wide therapeutic range, and exerts a bystander effect and radiosensitization both in vitro and in vivo. Thus, HSVtk/GCV system, alone or in combination with radiotherapy, may be a promising suicide gene therapy for thyroid carcinomas. (Endocrinology 138: [4577][4578][4579][4580][4581][4582][4583] 1997) 
T HYROID cancers are the most common endocrine malignancy, accounting for 1% of all cancers. In the case of well differentiated thyroid carcinomas, thyroidectomy followed by ablative radioiodine ( 131 I) treatment and TSH suppression is generally recommended as the treatment of choice. Despite excellent good prognosis of this type of thyroid carcinomas in general, approximately 30% of patients have recurrences, and half of patients who developed recurrences eventually succumb to the disease (1, 2) . In contrast, poorly differentiated or anaplastic thyroid carcinomas, a rare but highly lethal form of cancer with a median survival of less than 8 months, are refractory to the traditional treatments (1, 3) . Furthermore, an increase in highly aggressive childhood thyroid cancers has recently been reported in the Republic of Belarus after the Chernobyl nuclear power plant accident, and the incidence of late onset of radiation-induced thyroid carcinomas is also suspected to be very high in the future (4 -8) . Therefore, development of novel therapeutic approaches for thyroid carcinomas are urgently warranted; gene therapy may be a good candidate.
Strategies for gene therapy include selective prodrug activation by suicide genes, inhibition of activated oncogenes by antisense or ribozyme, transfer of tumor suppressor genes, and cytokine gene transfer (cancer vaccination) (9) . Gene therapy with prodrug/suicide gene combination involves the delivery of a suicide gene into cancer cells, making them sensitive to an appropriate prodrug. Herpes simplex virus thymidine kinase (HSV-tk) (10) , which is the most widely used suicide gene (9) , converts the antiviral prodrug of nucleotide analogs such as ganciclovir (GCV) and acyclovir to the monophosphorylated form, which is then converted to the toxic triphosphate form by endogenous cellar kinases that compete with normal nucleotides for DNA replication (10) . Thus, the expression of HSV-tk gene in mammalian cells renders them sensitive to GCV, thereby killing them by interfering with DNA synthesis. Retrovirus-and adenovirus-mediated HSV-tk/GCV treatment has been used in various tumor model systems (9, 11) . Furthermore, in addition to its direct cytotoxic effect, there may be at least two advantages of HSV-tk/GCV therapy. The first is that not only HSV-tk-expressing cells but also nontransduced cells can be killed, a phenomenon called the bystander effect (12) (13) (14) . The second is that phosphorylated GCV enhances the effect of radiation-induced cytotoxicity, a phenomenon termed radiosensitization (15) (16) (17) .
The present study was designed to evaluate the efficacy and toxicity of retrovirus-mediated HSV-tk gene therapy for treatment of thyroid carcinomas. We first tested whether transduction of HSV-tk gene in conjunction with GCV led to cell killing in vitro and tumor growth suppression in vivo using two thyroid carcinoma cell lines, FRO and WRO cells. Furthermore, the bystander effect and the radiosensitization effect were examined both in vitro and in vivo to clarify the therapeutic advantage of HSV-tk/GCV treatment in these cells.
Materials and Methods

Cell culture
Human follicular and anaplastic thyroid carcinoma cell lines, WRO and FRO (18) , were cultured with RPMI 1640 medium supplemented with 10% FBS and the appropriate antibiotics. The amphotropic and ecotropic retrovirus packaging line, PA317 and Psai-2, and mouse NIH-3T3 fibroblast cells were maintained in DMEM with 5% FBS.
Vector plasmid and retroviral transduction
The pLNCTK, which is a Moloney murine leukemia virus vector and contains the HSV-tk gene under the control of cytomegalovirus (CMV) promoter and neomycin phosphotransferase gene under control of simian virus 40 promoter, was provided by Dr. A. Ido (19) . The pLNCTK was transfected into Psai-2 cells using Lipofectamine (Life Technologies, Grand Island, NY). Forty-eight hours later, the medium containing ecotropic recombinant retrovirus was infected into PA317 cells. The virus-infected PA317 cells were selected in medium with 800 mg/liter G418 (Geneticin, Wako, Osaka, Japan), and G418-resistant colonies were cloned with cloning cylinders. Supernatant from the producer cell line with a titer of ϳ5 ϫ 10 7 colony-forming units/liter in NIH-3T3 cells was used to transduce FRO and WRO cells. The cells were incubated for 4 h and then selected with 800 mg/liter G418 for 2 weeks. The surviving cells were pooled and used for the subsequent experiments. FRO and WRO cells transduced with HSV-tk gene were designed for FRO-tk and WRO-tk, respectively.
Northern blot analysis
Total RNA was extracted by the guanidinium thiocyanatephenol-chloroform method. Twenty micrograms of total RNA were subjected to Northern blot analysis as previously described (20) . Membrane was sequentially hybridized with HSV-tk DNA and cyclophilin complementary DNA.
In vitro cytotoxic assays
The cells were seeded at density of 5 ϫ 10 2 cells/well for FRO and 1 ϫ 10 3 cells/well for WRO in 96-well microtiter plates. One day later (day 0), the cells were treated with various concentrations of GCV (Tanabe Seiyaku Co., Osaka, Japan) in 100 l fresh medium. Medium was replaced with the same medium on day 2. The cell survival was quantitated with a commercially available cell counting kit (Wako) on day 4. Survival ratios were expressed as percentages relative to untreated control values.
To determine the in vitro bystander effect, the cell mixtures of transduced and parent cells at different ratios were seeded in 48-well culture plates at 3 ϫ 10 4 cells/well. On the next day (day 0), when the cells were approximately 20 -30% confluent, with most cells having visible contact with adjacent cells, GCV was added at concentrations that are not toxic to parental cells. Medium was replaced with the same medium every other day. On day 6, viable cells were counted using the trypan blue exclusion test.
For radiosensitization studies, the cells plated in 10-cm cell culture dishes at a low density were exposed to 0.1 mg/liter GCV for 48 h before and after a single dose of ␥-irradiation with an EXS-300 ␥-irradiator (200 kV; 15 mA; filter, 0.5 mm aluminum and 0.5 mm copper; 0.47 Gy/min; Toshiba, Tokyo, Japan). Two weeks later, clonogenic survival was determined by counting colonies larger than 5 mm. Data were normalized to control levels to account for drug toxicity.
Detection of apoptotic cells
The cells were plated at a density of 3 ϫ 10 4 cells/well in six-well culture dishes and were incubated in the absence or presence of the IC 50 of GCV. Four days later, nuclear morphological changes in cells were examined using the fluorescent DNA-binding dye, Hoechst 33258, as previously described (21) . Cells were analyzed under fluorescence microscopy, and nuclei containing condensed chromatin were qualified as apoptotic cells. Three hundred cells were counted for each sample. Percent apoptotic cells were calculated as (total number of cells with apoptotic nuclei/total number of cells counted) ϫ 100.
In vivo tumor studies
Five-week-old male nude mice (Charles-River Japan, Tokyo, Japan) were injected sc on both sides of flanks with 1 ϫ 10 7 cells in 100 l PBS. Two weeks later, ip injections of various concentrations of GCV were performed daily for 2 weeks. In some experiments, xenografted tumors were irradiated with an EXS-300 ␥-irradiator (200 kV; 15 mA; filter, 0.5 mm aluminum; 1.41 Gy/min). The perpendicular tumor diameters were measured using calipers, and tumor volumes (V) were calculated by the formula of rotational ellipsoid: V ϭ A ϫ B 2 /2, where A is the longer diameter, and B is the smaller diameter (22) . The results were expressed as percentages relative to tumor size on day 0. None of the mice showed signs of wasting or other visible indications of toxicity.
All mice were maintained in Nagasaki University animal facility, and all animal studies were conducted in accordance with the principles and procedures outlined in the guide for the care and use of laboratory animals at Nagasaki University School of Medicine.
Statistical analysis was performed using unpaired Student's t test.
Results
Virus infection of human thyroid carcinoma cell lines, FRO and WRO cells
Expression of the HSV-tk gene was confirmed with Northern blot analysis. As shown in Fig. 1 , the 1.3-kb HSV-tk transcripts, which was initiated by CMV promoter and ter-minated by HSV-tk polyadenylation signal (19) , as well as larger genomic viral RNA were comparably detected in both virus-transduced FRO and WRO cells, but not in the parental cells. Relative amounts of messenger RNA (mRNA) on the blot were estimated by rehybridization to cyclophilin complementary DNA.
In vitro cytotoxicity
The cells expressing HSV-tk were first assayed for sensitivity to GCV by determining the IC 50 ( Fig. 2 and Table 1 ). There was no significant difference in cell growth between the parental and transduced cells. In dose-response experiments (Fig. 2, A and B) , the IC 50 shifted from 250 mg/liter (mean of two independent experiments) in FRO cells to 0.5 mg/liter in FRO-tk cells, and from 3,000 mg/liter in WRO cells to 0.09 mg/liter in WRO-tk cells. Thus, wide therapeutic ranges were obtained in HSV-tk/GCV treatment for thyroid carcinoma cells; the therapeutic indexes calculated as the IC 50 in parental cells/IC 50 in transduced cells were approximately 500 in FRO cells and 33,000 in WRO cells ( Table 1 ). The cell-killing effect of HSV-tk/GCV was also time dependent (Fig. 2, C and D) . The parental FRO cells seem to be slightly more sensitive to GCV than the parental WRO cells, while FRO-tk cells are more resistant to HSV-tk/GCV treatment compared with WRO-tk cells, which somehow does not fit the fact that cell growth is more rapid in FRO cells than in WRO cells, because toxicity of GCV is at least in part dependent on cellular mitotic activity.
We then evaluated whether nuclear fragmentations, a morphological characteristic of apoptosis, could be induced by GCV with Hoechst 33258 dye. As shown in Fig. 3 , GCV treatment significantly increased the percentage of apoptotic cells in FRO-tk (8.4 Ϯ 0.9% to 22.6 Ϯ 1.7%; P Ͻ 0.01) and WRO-tk (2.5 Ϯ 0.2% to 9.4 Ϯ 2.4%; P Ͻ 0.01) cells, suggesting that the cytotoxicity induced by HSV-tk/GCV is in part 
In vitro bystander effect
To investigate the in vitro bystander effect, HSV-tk-positive and -negative cells were mixed in different proportions and exposed to 50 mg/liter GCV for 6 days. A dose of 50 mg/liter GCV is not toxic to HSV-tk-negative cells (see Fig.  2 ). As shown in Fig. 4 , the cell mixtures containing only 20% of the transduced cells showed more than 90% growth inhibition by GCV in FRO/FRO-tk cells, indicating that HSVtk-expressing cells can exert an in vitro bystander effect. A less potent bystander effect was observed in WRO-tk cells; more than 90% growth inhibition was obtained in the cell mixture with 50% of transduced cells. Approximately equal amounts of connexin-43 mRNA expression, one of the commonly expressed connexins in the thyroids (23), was confirmed in FRO and WRO cells (data not shown).
In vitro radiosensitization
The extent of radiosensitization was assessed by comparing the percentage of survival cells after ionizing radiation with or without GCV administration in rapidly growing FRO-tk cells. To facilitate comparison, the levels of cytotoxicity were normalized to control levels to account for drug toxicity. The cells, cultured in the presence or absence of 0.1 mg/liter GCV, which alone produced only subtle cytotoxicity (see Fig. 2 ), were irradiated. As shown in Fig. 5 , FRO-tk cells treated with 0.1 mg/liter GCV were radiosensitized at a single dose of 10 Gy; that is, the percent cell survival was significantly lower in the cells treated with irradiation and GCV than in those treated with irradiation alone (9.2 Ϯ 1.8% vs. 1.0 Ϯ 2.0%; P Ͻ 0.01).
These in vitro data all together suggest that the HSV-tk/ GCV regimen appears to be very efficacious with a wide therapeutic range for treatment of thyroid carcinoma cell lines. Therefore, we then progressed to in vivo experiments to elucidate whether these in vitro effects could be reproduced in vivo using sc tumor models in nude mice with FRO cells.
In vivo cytotoxicity
FRO or FRO-tk cells (1 ϫ 10 7 ) were inoculated sc into both flanks of each mouse. Two weeks later (day 0 in Fig. 6 ), when small tumor nodules were present, mice were treated with various doses of GCV (0 -100 mg/kg BW) for 2 weeks. There was no significant difference in the tumor sizes between FRO and FRO-tk cells on day 0. As shown in Fig. 6 , daily administration of 100 mg/kg GCV did not inhibit the growth of FRO cells. In contrast, GCV treatment resulted in dose-and time-dependent tumor regression in HSV-tk-transduced cells. Tumor volumes in mice treated with 0, 2, 10, and 100 mg/kg GCV for 2 weeks were 1148 Ϯ 287%, 315 Ϯ 21%, 50 Ϯ 22%, and 0%, respectively, compared with that on day 0; the IC 50 was less than 2 mg/kg, and all tumors were completely eradicated in mice treated with 100 mg/kg GCV, in which tumors did not recur in the subsequent 2 weeks (data not shown).
In vivo bystander effect
Mice inoculated with the cell mixtures of FRO and FRO-tk cells at different ratios were used to evaluate the in vivo bystander effect. As shown in Fig. 7 , more than 70% and 90% of tumor growth inhibitions were observed in tumors containing only 20% and 50% of FRO-tk cells, respectively, demonstrating an in vivo bystander effect.
In vivo radiosensitization
Finally, mice with tumors composed of FRO-tk cells were treated with either GCV (5 mg/kg for 4 days), ionizing radiation (40 Gy), or both to evaluate the cooperative therapeutic effect of radiation and HSV-tk/GCV. GCV was given from days 0 -3, and a single dose of 40 Gy was administered on day 2 (Fig. 8) . GCV treatment alone did not affect tumor size, and 40 Gy ionizing radiation alone elicited approximately 85% tumor growth inhibition compared with that in untreated tumors. The combination of these two regimens produced significantly profound tumor regression compared with the effect of radiation alone (78 Ϯ 27% vs. 178 Ϯ 7% tumor volumes compared with day 0; P Ͻ 0.05). This cooperative effect of tumor regression is probably due to the radiosensitization effect observed in vitro. Therefore, all of the in vitro effects of HSV-tk/GCV therapy on thyroid carcinoma cells (direct cytotoxic effect, bystander effect, and radiosensitizing effect) were confirmed in in vivo experiments.
Discussion
In the present studies we evaluated the in vitro and in vivo therapeutic efficacy of the HSV-tk/GCV system, a widely used prodrug/suicide gene therapy, for treatment of thyroid carcinoma cells using a means of retrovirus-mediated gene transduction. In vitro dose-dependent experiments showed that transduction of the HSV-tk gene into thyroid carcinoma cell lines, FRO and WRO cells, rendered them 3-5 orders of magnitude more sensitive to GCV. Furthermore, complete in vitro cell death and in vivo tumor eradication were observed with 30 mg/liter and 100 mg/kg GCV, respectively. These concentrations can be achievable clinically (24) . Our data also indicate that apoptosis contributes at least partly to GCV induction of cell death, which is advantageous to the bystander effect (see below).
The bystander effect was readily observed in both in vitro and in vivo experiments. Thus, 20 -50% transduced cells led to more than 90% cell death. As phosphorylated GCV cannot pass freely through the plasma membrane, the bystander effect appears to be mediated by transport of phosphorylated GCV through gap junctions (12, 13) and/or phagocytosis of apoptotic vesicles (14) . The gap junction is constituted by a family of proteins, called connexins (23), and is the route for intercellular exchange of small hydrophilic molecules. Thus, expression of connexin-43 mRNA and induction of apoptotic cells after GCV administration probably contribute to this phenomenon (12) (13) (14) 25) . This phenomenon is clinically very important, as genetic modification of an entire tumor is at present impossible. Further, HSV-tk/GCV-induced tumor immunity in immune-competent cells (26 -28) , which cannot be expected in the nu/nu mice used in the present studies, may augment the in vivo bystander effect in clinical settings.
Our data also demonstrated that GCV enhances the sensitivity of HSV-tk-transduced cells to ionizing radiation. Such a prodrug-induced radiosensitization has recently been shown in glioma cells expressing the HSV-tk gene or the Escherichia coli cytosine deaminase gene (15) (16) (17) . Kim et al. (15) speculated that possible mechanisms for enhancement of radiation-induced cytotoxicity by GCV and 5-fluorocytosine may be to modify the DNA structure so as to make it more sensitive to radiation, to inhibit the repair of DNA lesions produced by irradiation, or both. From a clinical point of view, internal radioiodine treatment with 131 I as well as external radiation have long been widely used in patients with differentiated thyroid carcinomas whose intrinsic ability to concentrate iodine is preserved. Such tumors may benefit from the combination of HSV-tk gene therapy and radioiodine treatment. In this regard, it is of particular interest is to use a radiation-inducible promoter, such as egr-1, thymidine kinase, and tissue-type plasminogen activator (29) , to express a radiosensitizer, such as HSV-tk, in a tumor-specific manner.
As it has been reported that killing of HSV-tk-modified tumors by GCV may not be always complete (27, 30, 31) and that the bystander effect and radiosensitization cannot be seen in all types of cancer (12, 17) , our data suggest that the HSV-tk/GCV system seems to be an efficacious therapy for thyroid carcinoma cells. Thus, HSV-tk/GCV treatment may be a promising approach for thyroid carcinomas. It should be noted here, however, that as selection of an optimal prodrug/suicide gene system may vary in each cell type, it will be necessary to compare the relative efficacies of several prodrug/suicide gene therapy approaches (32, 33) , including Escherichia coli cytosine deaminase/5-fluorocytosine, human deoxycytisine kinase/1-␤-d-arabinofuranosylcytosine, etc., in treating thyroid carcinomas in the future.
While the present studies were in progress, Zeiger et al. (34) reported their preliminary results demonstrating GCVmediated killing of a rat normal thyroid cell line FRTL5, which stably expressed HSV-tk gene, in a tissue-specific manner using the thyroid-specific thyroglobulin promoter, which enables tissue-specific, but not tumor-specific, ablation of the thyroid glands (35) . Their strategy may be applicable for systemic treatment of distant metastatic thyroid carcinomas. In contrast, our studies indicate the potential of direct injection of recombinant virus encoding a suicide gene, which is derived from a viral promoter, as local treatment for thyroid carcinomas; because the thyroid glands are situated in anterior neck, regional neck lymph node metastases are often seen in patients with papillary type of thyroid carcinomas, and more importantly, death is caused by local invasion in most patients with anaplastic carcinomas (1) that do not usually express any differentiated markers of the thyroid cells. Virus-derived promoters, for example the CMV promoter used here, are indeed stronger than mammalian promoters.
In summary, the present studies demonstrate that the HSV-tk/GCV combination efficiently kills thyroid carcinoma cells not only by a direct cytotoxic effect but also by a bystander effect and enhances radiation-induced cell death both in vitro and in vivo. The very wide therapeutic range observed suggests that the HSV-tk/GCV regimen may be a good candidate for a novel approach in the treatment of thyroid carcinomas.
